These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8627865)

  • 81. Flutamide or thalidomide?
    Cohen MR
    Nursing; 2004 Jun; 34(6):18. PubMed ID: 15187694
    [No Abstract]   [Full Text] [Related]  

  • 82. Re: Editorial comment.
    Goldenberg SL; Gleave ME; Bruchovsky N; Rennie P
    J Urol; 1997 Jun; 157(6):2267. PubMed ID: 9146650
    [No Abstract]   [Full Text] [Related]  

  • 83. Androgen deprivation as a tumour-immunomodulating treatment.
    Gamat-Huber M; McNeel DG
    Nat Rev Urol; 2020 Jul; 17(7):371-372. PubMed ID: 32355324
    [No Abstract]   [Full Text] [Related]  

  • 84. Postorgasmic illness syndrome: two cases.
    Waldinger MD; Schweitzer DH
    J Sex Marital Ther; 2002; 28(3):251-5. PubMed ID: 11995603
    [TBL] [Abstract][Full Text] [Related]  

  • 85. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Small EJ
    J Urol; 1996 May; 155(5):1704-5. PubMed ID: 8627864
    [No Abstract]   [Full Text] [Related]  

  • 86. Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Small EJ
    J Urol; 1997 Aug; 158(2):552. PubMed ID: 9224356
    [No Abstract]   [Full Text] [Related]  

  • 87. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Fowler JE; Pandey P; Seaver LE; Feliz TP
    J Urol; 1995 Aug; 154(2 Pt 1):448-53. PubMed ID: 7541862
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 89. RE: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
    Walsh PC
    J Urol; 1996 May; 155(5):1705. PubMed ID: 8627865
    [No Abstract]   [Full Text] [Related]  

  • 90. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 91. [Basic and clinical characteristics of flutamide].
    Suzuki K; Nakazato H; Kurokawa K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716
    [No Abstract]   [Full Text] [Related]  

  • 92. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.
    Small EJ; Vogelzang NJ
    J Clin Oncol; 1997 Jan; 15(1):382-8. PubMed ID: 8996165
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW; Zlotta AR
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract]   [Full Text] [Related]  

  • 94. Molecular implications of the antiandrogen withdrawal syndrome.
    Moul JW; Srivastava S; McLeod DG
    Semin Urol; 1995 May; 13(2):157-63. PubMed ID: 7543690
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.